The antiemetic effects of magnetotherapy plus granisetron hydrochloride versus granisetron hydrochloride in patients with chemotherapy

  title={The antiemetic effects of magnetotherapy plus granisetron hydrochloride versus granisetron hydrochloride in patients with chemotherapy},
  author={Yongjun Zhang and Shengling Ma and Ai-Xing Zhang and Yan Sun and Wenlong Bao},
  journal={The Chinese-German Journal of Clinical Oncology},
ObjectiveThe aim of this study was to observe and compare the antiemetic effectiveness and adverse events of magnetotherapy plus 5-hydroxytryptamine (5-HT3) receptor inhibitor granisetron hydrochloride vs granisetron hydrochloride alone in patients with chemotherapy.MethodsSixty-four patients were randomized to receive either granisetron hydrochloride alone (control group: granisetron hydrochloride 3 mg intervenous infusion before chemotherapy, from the 1st day of chemotherapy course until the… 


A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. The Granisetron Study Group.
  • I. Smith
  • Medicine
    European journal of cancer
  • 1990
There was no relationship between the total dose and the number and severity of specific adverse events, and no differences in efficacy or safety between the two doses of granisetron were established.
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Single-dose palonosetron was as effective as ondansetron in preventing acute CINV following HEC, and with dexamethasone pre-treatment, its effectiveness was significantly increased over ondANSetron throughout the 5-day post-chemotherapy period.
Practical management of chemotherapy-induced nausea and vomiting.
Progress in CINV management must include a better understanding of its etiology and a focus on prevention, and many complementary and integrated modalities may be options.
Potential of Substance P Antagonists as Antiemetics
Except for monotherapy in acute cisplatin-induced emesis, this new class of drugs has proven to be highly effective in the control of both chemotherapy-induced nausea and vomiting, and postoperative nausea and vomit.
Clinical study of preoperative targeting magnetic chemotherapy in the advanced gastric cancers
The targeting magnetic chemotherapy combined with the magnetic fields, preoperatively administered in the treatment of the advanced gastric cancers, possesses a certain clinical value.
Phase I clinical study of a static magnetic field combined with anti‐neoplastic chemotherapy in the treatment of human malignancy: Initial safety and toxicity data
No increase in the severity of chemotherapy toxicity as measured by white blood cell count and platelet count was seen in the participants exposed to SMF compared to the historical control subjects, allowing the next group of subjects to be treated at the next dose level.